Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020
25 February 2020 - 12:30AM
Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that
management will host a conference call and webcast on Monday, March
2, at 4:30 p.m. ET to provide a corporate update and discuss
financial results for the fourth quarter and year ended December
31, 2019.
The call can be accessed by dialing 1-844-309-0618
(U.S. and Canada) or 1-661-378-9465 (international). The passcode
for the conference call is 6773016. To access the live webcast or
the subsequent archived recording, visit the “Investors” section of
the Ziopharm website at www.ziopharm.com. The webcast will be
recorded and available for replay on the Company’s website for two
weeks.
About Ziopharm Oncology, Inc. Ziopharm Oncology
is an immuno-oncology company focused on developing end-to-end
cost-effective solutions using its non-viral Sleeping Beauty
platform for TCR and CAR T-cell therapies and immune-stimulating
gene therapy with Controlled interleukin 12 (IL-12). The Sleeping
Beauty platform genetically modifies T cells with DNA plasmids to
express TCRs to target neoantigens inside and outside hotspots for
solid tumors and CAR to target CD19 for blood cancers using the
Company’s RPM to produce and release CAR-T as soon as the day after
gene transfer. The Sleeping Beauty platform is being advanced in
collaboration with the National Cancer Institute, The University of
Texas MD Anderson Cancer Center and Eden BioCell. The Company is
also developing its Controlled IL-12 platform, or Ad-RTS-hIL-12
plus veledimex, as monotherapy and in combination with immune
checkpoint inhibitors to treat brain cancer, including in
collaboration with Regeneron Pharmaceuticals.
Ziopharm Contact: Chris Taylor VP, Investor Relations and
Corporate Communications T: 617.502.1881 E:
ctaylor@ziopharm.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2024 to May 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about ZIOPHARM Oncology Inc (NASDAQ): 0 recent articles
More News Articles